Loading organizations...
§ Private Profile · Redwood City, CA, USA
Develops & manufactures molecular diagnostic blood tests for cardiovascular diseases, focused on coronary artery disease.
CardioDx is a Palo Alto, California-based molecular diagnostics organization that develops and manufactures specialized blood tests for cardiovascular diseases. The privately held enterprise generates its primary revenue through the commercialization of its flagship Corus CAD test, a diagnostic tool assisting healthcare providers in identifying coronary artery disease. Operating within the broader cardiovascular diagnostics sector, the company recorded $8 million in total sales for the fiscal year ending December 31, 2013. Following a brief postponement due to adverse market conditions, the firm revived its initial public offering plans in 2014 with a target to raise $75 million. To execute this specific public market strategy, the business engaged prominent financial institutions Jefferies and Piper Jaffray as its lead underwriters. Currently operating under the leadership of chief executive officer Khush Mehta, CardioDx was founded in 2003 by David Levison.
CardioDx has raised $227.0M across 6 funding rounds.
CardioDx has raised $227.0M in total across 6 funding rounds.
CardioDx has raised $227.0M across 6 funding rounds. Most recently, it raised $35.0M Other Equity in December 2014.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 18, 2014 | $35M Venture Round | Alberta Investment Management Corporation | — | Announced |
| Aug 27, 2012 | $58M Venture Round | — | Artiman Ventures, Asset Management Group, Bright Capital, DAG Ventures, GE Capital, Intel Capital, J.P. Morgan, Kleiner Perkins, Longitude Capital, Mohr Davidow Ventures, Pappas Ventures, RU COM, Temasek, TPG Biotech | Announced |
| May 11, 2011 | $60M Venture Round | — | Acadia Woods, Artiman Ventures, Bright Capital, J.P. Morgan, Patrick Enright | Announced |
| May 1, 2010 | $35M Series D | GE | Kleiner Perkins, SUE Siegel | Announced |
| Oct 1, 2008 | $20M Series C | — | Kleiner Perkins, SUE Siegel | Announced |
| Jul 1, 2006 | $19M Series B | — | Kleiner Perkins, SUE Siegel | Announced |
CardioDx has raised $227.0M in total across 6 funding rounds.
CardioDx's investors include Alberta Investment Management Corporation, Artiman Ventures, Asset Management Group, Bright Capital, DAG Ventures, GE Capital, Intel Capital, J.P. Morgan, Kleiner Perkins, Longitude Capital, Mohr Davidow Ventures, Pappas Ventures.
CardioDx is a molecular diagnostics company specializing in cardiovascular genomics, developing clinically validated gene expression tests for conditions like coronary artery disease (CAD), cardiac arrhythmias, and heart failure.[1][2] Its flagship product, Corus CAD, is a noninvasive blood test that assesses the likelihood of obstructive CAD in patients with chest pain symptoms, enabling clinicians to tailor care and reduce unnecessary invasive procedures.[1][2][4] The company serves cardiologists and patients through its CLIA-certified, CAP-accredited lab in California, with partnerships like Quest Diagnostics expanding national access.[2][5] Growth momentum included significant funding, such as $45 million raised for test development and a $5 million deal with GE Healthcare for co-development.[3][4]
CardioDx emerged in the molecular diagnostics space, headquartered initially in Palo Alto and later Redwood City, California, focusing on genomic innovations for cardiovascular care.[1][2] While specific founders are not detailed in available records, the company pursued early validation through trials like DISCERN for sudden cardiac event risk in arrhythmias and PREDICT for CAD gene expression tests.[1] Pivotal moments included launching Corus CAD as its initial product, securing CMS certification for its lab across all 50 states, and filing for IPO via SEC documentation, signaling commercial ambitions.[2][6] Strategic alliances, such as the national specimen-draw agreement with Quest Diagnostics in 2015, marked key traction in broadening test availability.[5]
CardioDx rides the wave of precision medicine and genomics in cardiology, where gene expression tests shift from reactive imaging to proactive, data-driven risk assessment amid rising cardiovascular disease burdens.[1][2] Timing aligns with healthcare's push for cost-effective alternatives to invasive procedures—Corus CAD helps avoid up to 30% of unnecessary catheterizations—fueled by falling sequencing costs and regulatory nods like CLIA/CAP accreditation.[2][6] Market forces favoring it include aging populations, post-2010s genomic tech maturation, and payer reimbursements for validated tests. It influences the ecosystem by pioneering blood-based cardiac diagnostics, inspiring competitors like XDx in transplant monitoring and pressuring incumbents to adopt molecular tools.[2]
CardioDx's trajectory hinges on expanding Corus CAD adoption and pipeline commercialization, potentially through acquisitions or further partnerships given its funding history and IPO pursuits.[3][6] Trends like AI-enhanced genomics and value-based care will amplify its edge, though competition from imaging AI (e.g., CT/MRI segmentation tools) and rivals in neuropathy diagnostics could challenge market share.[2] Its influence may evolve via broader genomic integration in cardiology, solidifying its role in patient-tailored care as seen in its foundational Corus CAD innovation.[1][4]